2024
Cryptosporidiosis in individuals with inflammatory bowel disease: a scoping review protocol
Liu B, Schnider A, DeArmond M, Banach D, Haubrich B. Cryptosporidiosis in individuals with inflammatory bowel disease: a scoping review protocol. BMJ Open 2024, 14: e086529. PMID: 39414295, PMCID: PMC11481120, DOI: 10.1136/bmjopen-2024-086529.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseJoanna Briggs InstituteBowel diseaseAssociated with significant morbidityModerate-to-severe diarrheaPublished clinical literatureTreatment of cryptosporidiosisPeer-reviewed journalsImmunosuppressive therapyInstitutional review boardRisk of infectionSignificant morbidityImmunocompromised individualsTheses GlobalCrohn's diseaseGastrointestinal infectionsGrey literatureReview protocolRisk factorsAdult studiesCochrane LibrarySelf-limitingPatientsEpidemiological correlationReview teamAn evaluation of outcomes and hospital readmissions among individuals with candidemia using statewide surveillance
Suschana E, Correa M, Meek J, Banach D. An evaluation of outcomes and hospital readmissions among individuals with candidemia using statewide surveillance. Infection Control And Hospital Epidemiology 2024, 45: 998-1002. PMID: 38561197, DOI: 10.1017/ice.2024.52.Peer-Reviewed Original Research
2023
841. An Evaluation of Outcomes and Hospital Readmissions Among Individuals with Candidemia in Connecticut (2019-2020)
Suschana E, Banach D, Meek J, Clogher P, Correa M. 841. An Evaluation of Outcomes and Hospital Readmissions Among Individuals with Candidemia in Connecticut (2019-2020). Open Forum Infectious Diseases 2023, 10: ofad500.886. PMCID: PMC10677324, DOI: 10.1093/ofid/ofad500.886.Peer-Reviewed Original ResearchHospital-onset infectionsEpisodes of candidemiaRisk factorsReadmission statusIncident episodesHospital readmissionHigh riskStatewide surveillance dataRetrospective cohort studyCommunity-onset infectionsCause of sepsisSpecific risk factorsNon-Candida albicans speciesClasses of infectionEvaluation of outcomesGeneral sepsisIncident admissionsReadmission characteristicsCandidemia episodesOverall morbidityCohort studySubsequent readmissionClinical factorsPrimary outcomeSignificant morbidity
2022
Epidemiology and outcomes of surgical site infections among pediatric liver transplant recipients
Banach DB, Lopez‐Verdugo F, Sanchez‐Garcia J, Tran A, Gomez‐Llerena A, Munoz‐Abraham A, Bertacco A, Valentino PL, Yoo P, Dembry L, Mulligan DC, Ekong UD, Emre SH, Rodriguez‐Davalos M. Epidemiology and outcomes of surgical site infections among pediatric liver transplant recipients. Transplant Infectious Disease 2022, 24: e13941. PMID: 35989545, DOI: 10.1111/tid.13941.Peer-Reviewed Original ResearchConceptsSurgical site infectionLiver transplant recipientsLiver transplantationBiliary complicationsGraft recipientsTransplant recipientsSite infectionRisk factorsOutcomes of SSIPediatric liver transplant recipientsLong-term graftPediatric liver transplantationRetrospective descriptive analysisPrimary endpointHospital daysPatient agePediatric populationPatient survivalSignificant causeComplicationsPatientsRecipientsOutcomesInfectionIncidence
2018
2396. Fosfomycin Resistance Among Carbapenem-Resistant Enterobacteriaceae Clinical Isolates in Connecticut, 2017
Snayd M, Leung V, Maloney M, Durante A, Macierowski B, Noel D, Muyombwe A, Razeq J, Banach D. 2396. Fosfomycin Resistance Among Carbapenem-Resistant Enterobacteriaceae Clinical Isolates in Connecticut, 2017. Open Forum Infectious Diseases 2018, 5: s714-s715. PMCID: PMC6253430, DOI: 10.1093/ofid/ofy210.2049.Peer-Reviewed Original ResearchState public health laboratoriesCRE isolatesNonsusceptible isolatesFosfomycin resistanceAntimicrobial Susceptibility Testing (EUCAST) criteriaCarbapenem-resistant Enterobacteriaceae infectionsOlder patient ageLimited treatment optionsResistance risk factorsSubstantial proportionEnterobacteriaceae clinical isolatesFosfomycin resistance ratePublic health laboratoriesLaboratory Standards InstituteSusceptibility testing criteriaCRE patientsPatient ageEnterobacteriaceae infectionsTreatment optionsRisk factorsResistance ratesWarrants evaluationCarbapenem resistanceBlaKPC geneCLSI criteria